Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

Literature DB >> 26847312

A Case of Dasatinib-Induced Nephrotic Syndrome in a Child with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia.

Young Tae Lim¹, Yong Jin Kim², Yong Hoon Park¹, Jeong Ok Hah¹, Jae Min Lee³.

Abstract

Entities: Chemical Disease Gene Species

Year: 2016 PMID： 26847312 PMCID： PMC4740552 DOI： 10.3349/ymj.2016.57.2.532

Source DB: PubMed Journal: Yonsei Med J ISSN： 0513-5796 Impact factor: 2.759

× No keyword cloud information.

8 in total

Review 1. Tyrosine kinase inhibitor use in pediatric Philadelphia chromosome-positive acute lymphoblastic anemia.

Authors: Stephen P Hunger
Journal: Hematology Am Soc Hematol Educ Program Date: 2011

2. Dasatinib-induced nephrotic-range proteinuria.

Authors: Eric Wallace; William Lyndon; Phillip Chumley; Edgar A Jaimes; Huma Fatima
Journal: Am J Kidney Dis Date: 2013-03-27 Impact factor: 8.860

3. Nephrotic syndrome associated with tyrosine kinase inhibitors for pediatric malignancy: case series and review of the literature.

Authors: Rebecca L Ruebner; Lawrence Copelovitch; Nicholas F Evageliou; Michelle R Denburg; Jean B Belasco; Bernard S Kaplan
Journal: Pediatr Nephrol Date: 2013-12-07 Impact factor: 3.714

4. Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases.

Authors: Vera Eremina; Manish Sood; Jody Haigh; András Nagy; Ginette Lajoie; Napoleone Ferrara; Hans-Peter Gerber; Yamato Kikkawa; Jeffrey H Miner; Susan E Quaggin
Journal: J Clin Invest Date: 2003-03 Impact factor: 14.808

Review 5. Tyrosine kinase inhibitors in pediatric malignancies.

Authors: Jeffrey M Skolnik; Peter C Adamson
Journal: Cancer Invest Date: 2007 Impact factor: 2.176

6. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia.

Authors: Kimmo Porkka; Perttu Koskenvesa; Tuija Lundán; Johanna Rimpiläinen; Satu Mustjoki; Richard Smykla; Robert Wild; Roger Luo; Montserrat Arnan; Benoit Brethon; Lydia Eccersley; Henrik Hjorth-Hansen; Martin Höglund; Hana Klamova; Håvar Knutsen; Suhag Parikh; Emmanuel Raffoux; Franz Gruber; Finella Brito-Babapulle; Hervé Dombret; Rafael F Duarte; Erkki Elonen; Ron Paquette; C Michel Zwaan; Francis Y F Lee
Journal: Blood Date: 2008-05-13 Impact factor: 22.113

7. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study.

Authors: Kirk R Schultz; W Paul Bowman; Alexander Aledo; William B Slayton; Harland Sather; Meenakshi Devidas; Chenguang Wang; Stella M Davies; Paul S Gaynon; Michael Trigg; Robert Rutledge; Laura Burden; Dean Jorstad; Andrew Carroll; Nyla A Heerema; Naomi Winick; Michael J Borowitz; Stephen P Hunger; William L Carroll; Bruce Camitta
Journal: J Clin Oncol Date: 2009-10-05 Impact factor: 44.544

8. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors: M Aricò; M G Valsecchi; B Camitta; M Schrappe; J Chessells; A Baruchel; P Gaynon; L Silverman; G Janka-Schaub; W Kamps; C H Pui; G Masera
Journal: N Engl J Med Date: 2000-04-06 Impact factor: 91.245

8 in total

4 in total

Review 4. Nephrotoxicity Associated with Novel Anticancer Agents (Aflibercept, Dasatinib, Nivolumab): Case Series and Nephrological Considerations.

Authors: Luca Piscitani; Vittorio Sirolli; Lorenzo Di Liberato; Manrico Morroni; Mario Bonomini
Journal: Int J Mol Sci Date: 2020-07-10 Impact factor: 5.923